Fig. 7: Model. Scheme describing the proposed mechanism of action of TROLL-2 and TROLL-3. | Nature Communications

Fig. 7: Model. Scheme describing the proposed mechanism of action of TROLL-2 and TROLL-3.

From: Pan-cancer analysis reveals TAp63-regulated oncogenic lncRNAs that promote cancer progression through AKT activation

Fig. 7: Model. Scheme describing the proposed mechanism of action of TROLL-2 and TROLL-3.

In normal cells (e.g. MCF10A cells) the tumour and metastasis suppressor TAp63 inhibits the expression of TROLL-2 and TROLL-3, while NOLC1 interacts with WDR26 and promotes the accumulation of WDR26 in the nucleus. In cancer cells (e.g. CA1D cells), instead, mutant p53 inhibits TAp63, thus allowing for the expression of TROLL-2 and TROLL-3. These lncRNAs counteract the interaction between NOLC1 and WDR26, while promoting the binding of WDR26 to AKT. As a consequence, the PI3K/AKT pathway is activated and can sustain tumour formation and progression.

Back to article page